fr   en

Browse by date
Or search by keyword
Date: 2010-07-26
Company: Cerenis Therapeutics (France) Groupe Novasep (France)
Investors: OSEO (France)
Amount: €10.7 million
Planned use: This funding will be used to finance the development of CER-001, a Cerenis HDL mimetic currently in Phase I clinical development for the treatment of post-acute coronary syndrome patients. It will also allow the further progression of this novel HDL therapy for orphan disease applications.
Other: Novasep and Cerenis Therapeutics have collaborated on the process development for CER-001 since 2007, focusing on downstream processing of the recombinant protein component. Under this funding and an expanded agreement, Novasep will be responsible for the global manufacturing of clinical and initial commercial supplies for the orphan drug development program.